Treatment with S-Adenosylmethionine and Nicotinamide Riboside Immune Function in Arts Syndrome: Case Report

Objectives

To assess whether co-therapy with S-adenosylmethionine (SAMe) and NR could improve clinical symptoms, immune cell function, and overall well-being in a child with Arts syndrome, beyond SAMe supplementation alone.

Journal

Molecular Genetics and Metabolism

Key Outcomes

• SAMe and NR co-therapy led to notable improvements in muscle strength, motor skills, and speech, with increased vocabulary and enhanced ability to engage in play.
• The patient experienced longer periods without respiratory infections and recovered more easily when infections occurred.
• Cotherapy also enhanced immune function, as observed via improved CD8 T-cell survival and increased cytokine responses, including IFN-γ and TNF-α.

Duration

SAMe therapy was initiated at 39 months of age, followed by the addition of NR at 43 months of age

Dose

SAMe: 400 mg

NR: 300 mg

Study Design

Prospective, single-patient, clinical case study of a 3-year-old male child with Arts syndrome (PRPS1 deficiency)